Caveolin‐1 overexpression is associated with aggressive prostate cancer recurrence
暂无分享,去创建一个
Yair Lotan | Jose A Karam | Pierre I Karakiewicz | Raheela Ashfaq | C. Roehrborn | Y. Lotan | R. Ashfaq | S. Shariat | P. Karakiewicz | J. Karam | Claus G Roehrborn | Shahrokh F Shariat | Claus G. Roehrborn
[1] M. Lisanti,et al. The Caveolin genes: from cell biology to medicine , 2004, Annals of medicine.
[2] A. Jemal,et al. Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.
[3] L. Truong,et al. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. , 1999, Cancer research.
[4] M. Drab,et al. Loss of Caveolae, Vascular Dysfunction, and Pulmonary Defects in Caveolin-1 Gene-Disrupted Mice , 2001, Science.
[5] T. Stamey,et al. Observations on the doubling time of prostate cancer. The use of serial prostate‐specific antigen in patients with untreated disease as a measure of increasing cancer volume , 1993, Cancer.
[6] Sun-Ja Kim,et al. Increased expression of caveolin‐1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma , 2004, BJU international.
[7] M. Kattan,et al. Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor β1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression , 2004, Clinical Cancer Research.
[8] M. Lisanti,et al. Expression of Caveolin-3 in Skeletal, Cardiac, and Smooth Muscle Cells , 1996, The Journal of Biological Chemistry.
[9] A. Partin,et al. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. , 1996, The American journal of surgical pathology.
[10] S. Woodman,et al. Caveolae: From Cell Biology to Animal Physiology , 2002, Pharmacological Reviews.
[11] C. Peschle,et al. Expression of Caveolin-1 Is Required for the Transport of Caveolin-2 to the Plasma Membrane , 1999, The Journal of Biological Chemistry.
[12] Pan‐Chyr Yang,et al. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. , 2002, The American journal of pathology.
[13] M. Lisanti,et al. Caveolin-1 in oncogenic transformation, cancer, and metastasis. , 2005, American journal of physiology. Cell physiology.
[14] G. Fiucci,et al. Up-regulation of Caveolae and Caveolar Constituents in Multidrug-resistant Cancer Cells* , 1998, The Journal of Biological Chemistry.
[15] L. Campbell,et al. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma , 2003, British Journal of Cancer.
[16] C. Roehrborn,et al. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. , 2004, The Journal of urology.
[17] M. Lisanti,et al. Upregulation of caveolin‐1 and caveolae organelles in Taxol‐resistant A549 cells , 1998, FEBS letters.
[18] T. Daskivich,et al. Recent progress in hormonal therapy for advanced prostate cancer , 2006, Current opinion in urology.
[19] William J Catalona,et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. , 2004, The Journal of urology.
[20] M. Kattan,et al. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. , 2003, Cancer research.
[21] T. Timme,et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells , 1998, Nature Medicine.
[22] T. Timme,et al. Combined c‐Myc and caveolin‐1 expression in human prostate carcinoma predicts prostate carcinoma progression , 2005, Cancer.
[23] T. Wheeler,et al. Elevated caveolin-1 levels in African-American versus white-American prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] D. Henson,et al. Practice protocol for the examination of specimens removed from patients with carcinoma of the prostate gland. A publication of the cancer committee, college of american pathologists. Task Force on the Examination of Specimens Removed From Patients With Prostate Cancer. , 1994, Archives of pathology & laboratory medicine.
[25] T. Wheeler,et al. Preoperative Serum Caveolin-1 as a Prognostic Marker for Recurrence in a Radical Prostatectomy Cohort , 2006, Clinical Cancer Research.
[26] A W Partin,et al. Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.
[27] V. Barresi,et al. Caveolin-1 in meningiomas: expression and clinico-pathological correlations , 2006, Acta Neuropathologica.
[28] M. Lisanti,et al. Expression and Characterization of Recombinant Caveolin , 1996, The Journal of Biological Chemistry.
[29] C. Roehrborn,et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma , 2004, Cancer.
[30] A. Partin,et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.
[31] T. Timme,et al. Caveolin‐1 expression is a predictor of recurrence‐free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients , 2003, Cancer.
[32] J. Engelman,et al. Genes encoding human caveolin‐1 and ‐2 are co‐localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers , 1998, FEBS letters.
[33] Michael W Kattan,et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. , 2002, The Journal of urology.
[34] M. Kattan,et al. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. , 2002, Cancer research.